CVE-2026-2092
An attacker with a valid signed SAML assertion can exploit this by crafting a malicious SAML response.
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.31%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
A flaw was found in Keycloak. Keycloak's Security Assertion Markup Language (SAML) broker endpoint does not properly validate encrypted assertions when the overall SAML response is not signed. An attacker with a valid signed SAML assertion can exploit this by crafting a malicious SAML response. This allows the attacker to inject an encrypted assertion for an arbitrary principal, leading to unauthorized access and potential information disclosure.
- CVSS 3.1
- 7.7 HIGHCVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:L/A:L
- EPSS
- 0.31% probability · 23th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-1287
- Affected
- redhat/build of keycloak
- Source
- secalert@redhat.com
References
- https://access.redhat.com/errata/RHSA-2026:3925Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3926Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3947Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3948Vendor Advisory
- https://access.redhat.com/security/cve/CVE-2026-2092Vendor Advisory
- https://bugzilla.redhat.com/show_bug.cgi?id=2437296Issue Tracking, Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3925Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3926Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3947Vendor Advisory
- https://access.redhat.com/errata/RHSA-2026:3948Vendor Advisory
- https://access.redhat.com/security/cve/CVE-2026-2092Vendor Advisory
- https://bugzilla.redhat.com/show_bug.cgi?id=2437296Issue Tracking, Vendor Advisory
- https://security.access.redhat.com/data/csaf/v2/vex/2026/cve-2026-2092.jsonVendor Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.